Form 4: Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, Reports Stock and Option Grants

Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• On January 2, 2025, Arturo Molina, the Chief Medical Officer of Protagonist Therapeutics, acquired 41,088 shares of common stock through a grant of restricted stock units and was granted options to purchase 49,862 shares of common stock.
• The restricted stock units vest in four equal annual installments starting January 15, 2026, contingent upon continued service.
• The stock options vest in 48 equal monthly installments following January 2, 2025, also contingent upon continued service.
• Following these transactions, Molina directly owns 87,532 shares of Protagonist Therapeutics common stock and options to purchase 49,862 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it incentivizes management. There are no indications of negative performance or concerns.

Positives

• The grant of restricted stock units and stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedules for both the restricted stock units and stock options incentivize continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules suggest an expectation of continued service from the Chief Medical Officer.

Industry Context

Stock option and restricted stock unit grants are common compensation practices in the biotechnology industry to attract and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules, like the 4-year vesting for restricted stock units and 48-month vesting for options, are typical to ensure long-term commitment.
• The specific number of shares and option grants would be determined by Protagonist Therapeutics' compensation committee based on factors such as performance, industry benchmarks, and company valuation.

Stakeholder Impact

• Shareholders may view the grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates